Spectral Med Stock Gross Profit
EDT Stock | CAD 0.56 0.01 1.75% |
Spectral Med fundamentals help investors to digest information that contributes to Spectral Med's financial success or failures. It also enables traders to predict the movement of Spectral Stock. The fundamental analysis module provides a way to measure Spectral Med's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Spectral Med stock.
Last Reported | Projected for Next Year | ||
Gross Profit | 662 K | 628.9 K | |
Gross Profit Margin | 0.41 | 0.78 |
Spectral | Gross Profit |
Spectral Med Company Gross Profit Analysis
Spectral Med's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Spectral Med Gross Profit | 983 K |
Most of Spectral Med's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Spectral Med is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Spectral Gross Profit Driver Correlations
Understanding the fundamental principles of building solid financial models for Spectral Med is extremely important. It helps to project a fair market value of Spectral Stock properly, considering its historical fundamentals such as Gross Profit. Since Spectral Med's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spectral Med's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spectral Med's interrelated accounts and indicators.
Click cells to compare fundamentals
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition |
According to the company disclosure, Spectral Med reported 983 K of gross profit. This is 99.96% lower than that of the Biotechnology sector and 99.89% lower than that of the Health Care industry. The gross profit for all Canada stocks is 100.0% higher than that of the company.
Spectral Med Current Valuation Drivers
We derive many important indicators used in calculating different scores of Spectral Med from analyzing Spectral Med's financial statements. These drivers represent accounts that assess Spectral Med's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Spectral Med's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 162.5M | 94.2M | 55.5M | 99.8M | 118.4M | 124.3M | |
Enterprise Value | 161.8M | 89.0M | 47.2M | 98.1M | 124.0M | 130.2M |
Spectral Fundamentals
Return On Equity | -9.74 | ||||
Return On Asset | -0.93 | ||||
Operating Margin | (9.46) % | ||||
Current Valuation | 163.21 M | ||||
Shares Outstanding | 282.82 M | ||||
Shares Owned By Insiders | 18.13 % | ||||
Shares Owned By Institutions | 12.95 % | ||||
Number Of Shares Shorted | 95.22 K | ||||
Price To Earning | (16.07) X | ||||
Price To Book | 49.87 X | ||||
Price To Sales | 84.80 X | ||||
Revenue | 1.6 M | ||||
Gross Profit | 983 K | ||||
EBITDA | (13.96 M) | ||||
Net Income | (15.66 M) | ||||
Cash And Equivalents | 3.8 M | ||||
Cash Per Share | 0.02 X | ||||
Total Debt | 8.56 M | ||||
Debt To Equity | 16.30 % | ||||
Current Ratio | 6.95 X | ||||
Book Value Per Share | (0.06) X | ||||
Cash Flow From Operations | (10.72 M) | ||||
Short Ratio | 1.04 X | ||||
Earnings Per Share | (0.10) X | ||||
Target Price | 2.0 | ||||
Number Of Employees | 29 | ||||
Beta | 1.0 | ||||
Market Capitalization | 161.2 M | ||||
Total Asset | 5.21 M | ||||
Retained Earnings | (125.44 M) | ||||
Working Capital | (6.12 M) | ||||
Net Asset | 5.21 M |
About Spectral Med Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spectral Med's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spectral Med using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spectral Med based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Spectral Med
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spectral Med position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spectral Med will appreciate offsetting losses from the drop in the long position's value.Moving against Spectral Stock
0.89 | PYPL | PayPal Holdings CDR | PairCorr |
0.84 | INTC | INTEL CDR | PairCorr |
0.74 | TSLA | Tesla Inc CDR | PairCorr |
0.73 | NVDA | NVIDIA CDR | PairCorr |
0.65 | GOOG | Alphabet CDR | PairCorr |
The ability to find closely correlated positions to Spectral Med could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spectral Med when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spectral Med - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spectral Med to buy it.
The correlation of Spectral Med is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spectral Med moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spectral Med moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spectral Med can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Spectral Stock
Spectral Med financial ratios help investors to determine whether Spectral Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spectral with respect to the benefits of owning Spectral Med security.